24.04.2023 - LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, . Seite 1
Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors
Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors
THOUSAND OAKS, Calif., Feb. 01, 2021 Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors.
Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are delighted to have Camilla join our board during this exciting time for Dyve. Our lead candidate, DYV700, in Phase 2 clinical development, has shown best-in-class potential for the treatment of acute gout flares and is on track for completion of Phase 2 in the first half of this year. With DYV700 and our emerging pipeline of additional Phase 2 candidates, Camilla’s wealth of leadership experience in product strategy, portfolio management, regulatory affairs, and business development will be invaluable as we continue to build momentum. We look forward to Camilla’s immediate contribution